RE:RE:RE:RE:RE:RocheCanadafan,
I agree with you about the use of Roche's trademark - ONC must have their approval.
I disagree with you that it is ONC's communication team that is responsible for the slide deck, rather than Matt Coffey. Remember, ONC is a microcap biotech with about a dozen employees. MC has absolutely nothing to due day after day, week after week, except wait for the phone to ring. He has time and he is ultimately 100% responsible for the accuracy of every word on the investor presentation.
Given that Roche is identified as a "collaborator" for ONC's pending P3 panc trial, this can only mean that Roche and ONC are "partners" and also that Roche has given ONC the go ahead to use their CPI for a P3 combined with pelareorep. This is excellent news and ONC should do more to let the world know rather than to slip it in discretely on one page of 30 in an investor presentation.
As I have also suggested, Roche would in no way partner with a microcap biotech on a P3 trial without ensuring that the P3 has adequate funding and expertise in place.
Interestingly, ONC has neither the necssary funding nor expertise in place to conduct any such P3 trial.
Connecting the dots, this can only mean that Roche is sponsering the trial (ie. funding and running).
But I highly doubt that is true as of this moment and that is why I wonder aloud at Roche's trademark loacated at that particular place on the investor presentation.
Someone with a line to MC or ONC may want to ask them?
I predict that without a near term announcement regarding the P3 we will soon see an edit to this page on the slide deck.
Hope I'm wrong. It will be great to have some news this week.